

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

### PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 75981

Title: Pre-sarcopenia and Mac-2 Binding Protein glycosylation isomer as predictors of

re[NM1] currence and prognosis in early-stage hepatocellular carcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05085435

Position: Peer Reviewer

Academic degree: MD

Professional title: Lecturer

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Japan

Manuscript submission date: 2022-02-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-04 12:37

Reviewer performed review: 2022-03-13 21:24

Review time: 9 Days and 8 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ ] Minor revision [ Y] Major revision [ ] Rejection</li> </ul>
Re-review	[ ]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

1. The title is redundant. 2. Abbreviations should be mentioned in first site for example DCP in abstract, ALBI in results, etc. 3. Wrong or inappropriate sentence structure such as " Pre-sarcopenia was also an independent poor prognostic factor in abstract", "Notably, HCV has been able to eliminate viruses in almost all cases using direct-acting antivirals (DAAs) in introduction", etc. 4. Core tip should be more informative about your study. 5. On page 7, the guidelines reference should be cited. 6. On page 8, SMI reference should be cited. 7. The 1st paragraph on page 12 is wrongly structured. 8. The 1st paragraph on page 13 has a contradictory data to the literature. 9. The discussion should be more organised.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 75981

Title: Pre-sarcopenia and Mac-2 Binding Protein glycosylation isomer as predictors of

re[NM1] currence and prognosis in early-stage hepatocellular carcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05352073

Position: Peer Reviewer

Academic degree: MD

Professional title: Director, Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2022-02-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-15 07:21

Reviewer performed review: 2022-03-27 11:45

Review time: 12 Days and 4 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[ ]Yes [Y]No



# Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

This manuscript is a retrospective real world clinical research, it reviewed 160 hepatocellular carcinoma patients and revealed that pre-sarcopenia and M2BPGi are prognostic and recurrence markers for hepatocellular carcinoma without HCV infection. Generally, it is a worthwhile and innovative clinical research. Here are some detailed comments. First, M2BPGi has reported to be a predictive serum marker as well as prognostic marker for hepatocellular carcinoma in various literatures. However, in this manuscript, hepatocellular carcinoma patients was subdivided into HCV positive and HCV negative groups, and came into a specific conclusion. It is innovative and useful for clinical work as well. Second, it is a retrospective study with sufficient amount of participants and sufficient follow up period. The statistical methods are rigorous. The selection of outcomes is reasonable and practical. All these factors can contribute to a Third, minor language polishing is recommended. For well grounded conclusion. example, "HCV-negative patients with primary HCC treated with RFA and lower M2BPGi contributed to tumor recurrence and survival". This sentence are recommended to be changed into "lower M2BPGi contributed to lower tumor recurrence rate and longer survival period".